Company intelligence / Profile preview
Nouscom
Basel, Switzerlandnouscom.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 2
01
Overview
Nouscom’s clinical data show its viral vector-based neoantigen vaccines are safe, highly immunogenic, induce durable T cell responses, and demonstrate anti-tumor activity. In metastatic melanoma patients treated with NOUS‑PEV plus pembrolizumab, partial responses were observed in the majority of evaluable patients. For NOUS‑209 in Lynch Syndrome carriers and MSI-H solid tumors, updated safety/immunogenicity data are positive with ongoing randomized studies expected to read out soon.
- Therapeutic areas
- OncologyHematology
- Modalities
- Viral vector-based vaccines (recombinant adenovirus from non-human great apes and Modified Vaccinia Virus Ankara)Neoantigen-based immunotherapies (personalized and off-the-shelf cancer vaccines)Immunomodulators
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Merck & Co., Inc. (“MSD”)—clinical trial collaboration on pembrolizumab supply for combination studies with NOUS–209National Cancer Institute—collaboration on Lynch syndrome studyJanssen Research & Development/Bristol Myers Squibb—licensee partners for VAC–85135
Beyond the preview
Go deeper on Nouscom.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nouscom.